Femasys Inc. filed a Form 8-K on November 2, 2026, reporting the resignation of director Kenneth D. Eichenbaum, M.D., M.S.E. and the appointment of John Moorhead as a Class II director of the company, both effective October 30, 2026.

Key Highlights

  • Director resigned: Kenneth D. Eichenbaum, M.D., M.S.E. resigned from the Femasys Board of Directors effective October 30, 2026, in connection with Pointillist Global Macro Series of Pointillist Partners LLC's termination of its right to nominate a board member under a Securities Purchase Agreement dated November 3, 2025.
  • New director appointed: John Moorhead was appointed to the Board effective October 30, 2026, pursuant to board designation rights held by Nantahala Capital Management, LLC under a side letter agreement dated August 7, 2026.
  • Committee assignments: Mr. Moorhead will serve on the Audit Committee and Compensation Committee, and the Board determined he qualifies as an independent director under Nasdaq listing requirements.
  • Term length: Mr. Moorhead will hold office as a Class II director for a term expiring at the 2029 annual meeting, at which time he will stand for election by stockholders.
  • No disagreement cited: According to the filing, Dr. Eichenbaum's resignation "was not due to any dispute or disagreement with the Company, or on any matter relating to the Company's operations, policies or practices."
  • Compensation terms: Mr. Moorhead will receive the applicable annual retainer and equity awards under the company's director compensation policy and will be entitled to enter into an indemnification agreement with the company.

Board Changes at Femasys: Eichenbaum Out, Moorhead In as of October 30, 2026

Femasys Inc. (NASDAQ:FEMY), a Delaware-incorporated company headquartered in Suwanee, Georgia, disclosed two simultaneous board-level changes in this Form 8-K filed November 2, 2026, with both actions taking effect October 30, 2026. According to the filing, Kenneth D. Eichenbaum, M.D., M.S.E. resigned as a director after Pointillist Global Macro Series of Pointillist Partners LLC elected to terminate its nomination right under a Securities Purchase Agreement originally dated November 3, 2025. The filing states the resignation was unrelated to any dispute or disagreement with the company.

In place of Dr. Eichenbaum, the Board appointed John Moorhead, exercising designation rights granted to Nantahala Capital Management, LLC as Lead Investor under a side letter agreement dated August 7, 2026. The filing notes that the Lead Investor's right to designate board members is "subject to certain minimum ownership thresholds of the Company's outstanding common stock set forth in the Side Letter." The company agreed under that side letter to appoint up to two individuals designated by the Lead Investor. The filing states there are no family relationships between Mr. Moorhead and any director or executive officer of the company, and no other arrangements or understandings pursuant to which he was selected.

According to the filing, Mr. Moorhead brings more than two decades of experience in consumer marketing, brand development, product innovation, and finance. He spent 12 years at Unilever's Seventh Generation, rising from Associate Brand Manager to Chief Marketing Officer. Most recently, he served as Head of Marketing, North America, at SBM Life Science. Earlier in his career, he was a Senior Financial Analyst at CAT Partners. He holds a bachelor's degree from Williams College and an MBA from Babson College. A press release announcing the appointment was furnished as Exhibit 99.1 to the filing.

What Was Disclosed

Femasys reported the October 30, 2026 resignation of director Kenneth D. Eichenbaum and the same-day appointment of John Moorhead as a Class II director through 2029, with Moorhead designated by lead investor Nantahala Capital Management, LLC under a previously filed side letter.